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Abstract
Introduction: This article reports the content validation of a Critical Appraisal Tool designed to Review the quality of Analgesia
Studies (CATRAS) involving subjects incapable of self-reporting pain and provide guidance as to the strengths and weakness of
findings. The CATRAS quality items encompass 3 domains: level of evidence, methodological soundness, and grading of the pain
assessment tool.
Objectives: To validate a critical appraisal tool for reviewing analgesia studies involving subjects incapable of self-reporting pain.
Methods: Content validation was achieved using Delphi methodology through panel consensus. A panel of 6 experts reviewed the
CATRAS in 3 rounds and quantitatively rated the relevance of the instrument and each of its quality items to their respective domains.
Results:Content validation was achieved for each item of the CATRAS and the tool as a whole. Item-level content validity index and
kappa coefficient were at least greater than 0.83 and 0.81, respectively, for all items except for one item in domain 2 that was later
removed. Scale-level content validity index was 97% (excellent content validity).
Conclusions: This 67-item critical appraisal tool may enable critical and quantitative assessment of the quality of individual
analgesia trials involving subjects incapable of self-reporting pain for use in systematic reviews and meta-analysis studies.
Keywords: Critical appraisal tool, Analgesia, Pain
1. Introduction
The scientific literature contains many examples of inconsistencies
regarding theanalgesic efficacyof treatments forpain. It is theauthors’
opinion that many of these inconsistencies arise due to variations in
the quality and rigour with which each study was designed.
Determining the quality of published studies of analgesic
interventions is difficult, particularly those involving animal pain
models, hampering efforts to draw meaningful clinical conclu-
sions from published findings and to perform systematic reviews
of the literature.34,40 Frameworks are needed to ensure greater
consistency in experimental design to allow for more accurate
comparison of findings.40 The Initiative on Methods, Measure-
ment, and Pain Assessment in Clinical Trials (IMMPACT) has
developed consensus reviews and recommendations for
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improving the design, execution, and interpretation of clinical
analgesia trials in self-reporting humans.9,33,48 Despite this,
recommendations for animals, as well as for humans incapable
of self-reporting pain are still lacking.
Descriptors of quality currently used to critically appraise
scientific literature typically include schemes for assessing the
level of evidence (LOE) and methodological soundness.2,14 The
LOE for a particular study is assigned according to the study
design and its inherent likelihood to exclude bias. Grading of the
methodological soundness of a study is typically based on how
closely it conforms to established standards for study design. The
“2011 Levels of Evidence” established by the Oxford Centre for
Evidence-Based Medicine (OCEBM) and the Grading of Recom-
mendations Assessment, Development, and Evaluation (GRADE)
system are 2 of the most universally recognised ranking
systems.7,17,19,43 These critical appraisal tools (CATs) include
checklists with specific questions and/or scales for scoring
components of quality, which are combined to give a summary
score.24
Current “gold-standard” pain assessment tools (PATs) rely on self-
reporting, requiring an individual subject to both process external
information and communicate this personal experience. In relation to
subjects incapable of self-reporting pain such as noncommunicative
or cognitively impaired human patients or pain in animal, this is not
possible. In these situations, the assessment of pain involves
changes in behavioural or physiological parameters. However, their
use canbeassociatedwith considerable shortcomings. Theymaybe
unreliable, hampered by observational bias, or influenced by disease
processes or pharmacological interventions. Current evidence
indicates that treatment of pain is inadequate in human patients
incapable of self-reporting pain as well as animal, largely because of
inadequate methods of pain assessment.23,27,32,39,44,52 This brings
into question the accuracy and validity of findings from published
studies using non–self-reporting PATs. Several assessment techni-
ques have been designed specifically for the grading of PATs in
noncommunicative human patients; these primarily evaluate the
psychometric properties of PATs against: item selection and content
validation, reliability, validity, feasibility, and relevance or impact on
patient outcomes.16,38,52
Critical appraisal and interpretation of findings from analgesia
studies remains challenging because of the lack of a single CAT
for evaluating all domains (ie, LOE, methodological soundness,
and grading of the PATs). The aim of the present work was to
construct and validate a CAT that incorporated the aforemen-
tioned 3 domains to assess the quality of individual analgesia trials
and provide quantification of quality for use in systematic reviews
andmeta-analysis studies focusing on subjects incapable of self-
reporting pain. Importantly, this CAT will assess whether the
methodologies used by a study conform to appropriately high
scientific standards, independent of the species being studied.
This study reports the content validation of this CAT referred to as
“CATRAS” for Critical Appraisal Tool for Reviewing Analgesia
Studies.
2. Methods
A working group identified and adapted potential domains and
items to form the preliminary version of the CATRAS. The weight
of each domain and associated item scores were assigned by the
working group at this stage. This study reports the initial validation
of the CATRAS by a panel of experts and comprised 2 phases: (1)
development of consensus and preliminary agreement of content
and (2) content validation. An overview of these phases is
represented in Figure 1.
2.1. Identification and adaption of the domains and items
In 2014, the working group that comprised 2 of the authors (L.N.
W. and S.H.B.) identified 3 domains, which would form the
analytical scope of the CATRAS, and ultimately the framework
used to critically appraise published analgesia studies.
(1) Level of evidence (CATRAS step 1, domain 1)—The working
group adopted without modification, an LOE classification
system that was previously used by a landmark systematic
review initiative, the Reassessment Campaign on Veterinary
Resuscitation (RECOVER). The LOE classification used by the
RECOVER initiative was itself modified from a major human
review group, the 2010 International Liaison Committee on
Resuscitation (ILCOR 2010).4,31 This domain contained 6
items (LOE 1–6), which are characterised by criteria presented
in Table 1, domain 1. The LOE of a study must be established
before assessment of its methodological soundness.
(2)Methodological soundness (CATRAS step 2, domain 2)—The
list of quality items contributing to this domain was adopted
with minor modifications from that used in the RECOVER
initiative process, which was originally derived from CATs
designed by the OCEBM.4,6 Modifications included the
addition of the following 2 quality item questions to each of
the 5 possible categories (A–E): “Was conflict of interest
stated?” and, “Was the statistical methodology of the study
appropriate? (If “NO,” please justify).”
(3)Grading of the PAT (CATRAS step 3, domain 3)—The purpose of
domain 3 is to provide critical appraisal of the PAT used in a study
being evaluated. To assess the quality of the PAT used within an
analgesia study being reviewed, domain 3 of the CATRAS
requires the investigator to review the original or revised literature
describing the development, refinement, or validation of the PAT.
To achieve the third domain of the CATRAS, a CAT was
developed based on a psychometric scoring system developed
and validated to evaluate PATs used in noncommunicative
critically ill human patients.16 The original psychometric scoring
system used by Gélinas (2013) incorporated the GRADE system
methodology.16,21 The content of the psychometric scoring
system used by Gélinas (2013) was adopted largely unmodified
from the original version, with only the following minor changes
being made by the working group: substitution of the word
“scale” for “Pain Assessment Tool” OR “PAT” to maintain
continuity with nomenclature in other domains; all references to
“ICU patients” were removed to maintain relevance to more than
just ICU patients; anthropological examples used within the
scoring legendof itemswithin the original toolwere substituted for
species’ neutral descriptors; a minor change was also made to
the terminology of the question in item 3.5 from “Discriminant
validation” to “Sensitivity to change” as the working group
considered that this change provided greater clarity.
2.2. Recruitment of the panel of experts
A panel of 6 internationally recognised experts from different
institutions was established to critique the CATRAS. The expert
panel comprised 6 of the authors (T.B., J.T.B., B.D.X.L., S.A.R.,
P.V.M.S., and P.M.T.). Panel members were selected based on
their professional certifications and credentials, clinical experi-
ence and publication profile in translational research, veterinary
pain management, and PAT construction.
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2.3. Development of consensus
The study used Delphi methodology to develop consensus from
a panel of experts, bymeans of surveys conducted over 3 rounds,
to ensure that the 3 domains and items generated in the
development of the CATRAS were not merely a function of the
smaller working group by means of surveys conducted over 3
rounds.22,29 The objective of the first round was to gauge the
completeness of the domains (and items within each) to assess
adequately the quality of analgesia studies. Definitions for the
domains and items within each were provided to enable
comparison of each domain and item against its definition.
Members of the expert panel were invited to contribute as many
ideas as they wished in response to 2 open-ended questions
regarding quality in analgesia studies: (1) “Are there additional
domains beyond those already encompassed (ie, LOE, method-
ological soundness, and grading of the PAT), which you consider
integral in comprehensively assessing the quality of analgesia
studies? If YES, please list and explain your answer.” (2) Within
the existing 3 domains, what factors not already encompassed by
existing items (if any), do you consider important for assessing the
quality of analgesia studies?”
In the second round, the responses obtained in round 1 were
collated into one document by the working group and redistributed
Figure 1.Diagrammatical representation of the sequence of tasks in this study. S-CVI, scale-level content validity index. LNW, Leon N.Warne; SHB, Sébastien H.
Bauquier; DXL, B. Duncan X. Lascelles; TB, Thierry Beths; SAR, Sheilah A. Robertson; PVMS, Paulo V.M. Steagall; JTB, Juliana T. Brondani; PMT, Polly M. Taylor.
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Table 1
CATRAS quality items and associated item-level content validity index (I-CVI) values and kappa coefficients (k).
Domain 1: level of evidence (LOE)
Study characteristics LOE I-CVI k Evaluation
Randomised negative- or positive-controlled
trials (RCTs), or meta-analyses of RCTs in the
target species:
Clinical studies that prospectively collect data
and randomly allocate the subjects to
intervention or control groups, or meta-
analyses of these studies.
1 1 1 Excellent
Prospective clinical studies in the target species
using concurrent controls (ie, controls recruited
at the same time as experimental subjects)
without randomisation. These studies can be:
1. Interventional clinical: Include subjects
who are allocated to intervention or control
groups concurrently, but in a nonrandom
fashion OR
2 1 1 Excellent
2. Observational clinical: Include cohort and
case–control studies.
Experimental laboratory study in the target
species:
These could include, but are not limited to
randomized, blinded, and controlled
studies.
3 1 1 Excellent
Clinical retrospective studies in the target
species:
The study and control groups have been
selected from a previous period in time
(historical controls).
4 0.83 0.81 Excellent
Case series and case reports in the target
species:
A single group of subjects exposed to the
intervention (or factor under study), but
without a control group.
5 1 1 Excellent
Studies, experimental or clinical, that are not
directly related to the specific target species or
target population.
These could be different species/populations,
including experimental models in nontarget
species.
6 0.83 0.81 Excellent
Domain 2: methodological soundness I-CVI k Evaluation
[A] Randomised controlled trials
Was the randomisation list concealed? 1 1 Excellent
Were all subjects who entered the trial
accounted for at its conclusion?
1 1 Excellent
Were the subjects analysed in the groups to
which they were randomised?
0.83 0.81 Excellent
Were owners, investigators, and evaluators
“blinded” to which treatment was being
received?
1 1 Excellent
Aside from the experimental treatment, were
the groups treated equally?
0.83 0.81 Excellent
Were the groups similar at the start of the
trial?
1 1 Excellent
Is the relevance to the question being posed
high (ie, no confounding factors such as
concomitant drug administration or
intervention, which could bias the
relevance to the question, the study directly
addresses the question)?
1 1 Excellent
Is there a high likelihood that the
administered drug (or intervention) will
have clinically relevant analgesic effect?
0.83 0.81 Excellent
Was conflict of interest stated? 1 1 Excellent
Was ethical/institutional review board
approval of the study stated?
1 1 Excellent
Was the statistical methodology of the study
appropriate? If “NO,” please justify:
1 1 Excellent
(continued on next page)
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Table 1 (continued)
CATRAS quality items and associated item-level content validity index (I-CVI) values and kappa coefficients (k).
Domain 2: methodological soundness I-CVI k Evaluation
[B] Clinical studies using concurrent controls
without randomisation
Were comparison groups clearly defined? 1 1 Excellent
Were outcomes measured in the same
(preferably blinded) objective way in both
groups?
1 1 Excellent
Were known confounders identified and
appropriately controlled for?
1 1 Excellent
Was follow-up of subjects sufficiently long
and complete?
1 1 Excellent
Is the relevance to the question being posed
high?
1 1 Excellent
Is there a high likelihood that the
administered drug (or intervention) will
have clinically relevant analgesic effect?
1 1 Excellent
Was conflict of interest stated? 1 1 Excellent
Was ethical/institutional review board
approval of the study stated?
1 1 Excellent
Was the statistical methodology (including
sample size) of the study appropriate? If
“NO,” please justify:
1 1 Excellent
[C] Experimental laboratory studies in target
species
Is the study a randomised controlled trial
(RCT)?
1 1 Excellent
Is the study a randomised trial (including
RCT)?
1 1 Excellent
Is the relevance to the question being posed
high?
1 1 Excellent
Is there a high likelihood that the
administered drug (or intervention) will
have clinically relevant analgesic effect?
1 1 Excellent
Was conflict of interest stated? 1 1 Excellent
Was ethical/institutional review board
approval of the study stated?
1 1 Excellent
Was the statistical methodology (including
sample size) of the study appropriate? If
“NO,” please justify:
1 1 Excellent
[D] Retrospective clinical studies using controls
without randomisation
Were comparison groups clearly defined? 0.83 0.81 Excellent
Were outcomes measured in the same
objective way in both groups?
0.83 0.81 Excellent
Were known confounders identified and
appropriately controlled for?
1 1 Excellent
Was follow-up of subjects sufficiently long
available and complete?
1 1 Excellent
Were criteria used to include subjects in or
exclude subjects from the study clearly
stated?
1 1 Excellent
Is the relevance to the question being posed
high?
1 1 Excellent
Is there a high likelihood that the
administered drug (or intervention) will
have clinically relevant analgesic effect?
1 1 Excellent
Was conflict of interest stated? 1 1 Excellent
Was ethical/institutional review board
approval of the study stated?
0.83 0.81 Excellent
Was the statistical methodology (including
sample size) of the study appropriate? If
“NO,” please justify:
1 1 Excellent
[E] Clinical studies without controls
Were outcomes measured in an objective
way?
1 1 Excellent
Were known confounders identified and
appropriately controlled for?
1 1 Excellent
Was follow-up of subjects sufficiently long
and complete?
1 1 Excellent
Is the relevance to the question being posed
high?
1 1 Excellent
(continued on next page)
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Table 1 (continued)
CATRAS quality items and associated item-level content validity index (I-CVI) values and kappa coefficients (k).
Domain 2: methodological soundness I-CVI k Evaluation
Is there a high likelihood that the
administered drug (or intervention) will
have clinically relevant analgesic effect?
1 1 Excellent
Was conflict of interest stated? 1 1 Excellent
Was ethical/institutional review board
approval of the study stated?
1 1 Excellent
Was the statistical methodology (including
sample size) of the study appropriate? If
“NO,” please justify:
1 1 Excellent
Domain 3: grading of the pain assessment tool (PAT)
Question Scoring legend I-CVI k Evaluation
1.1 Does the PAT assess multiple important indicators
or dimension of pain?
2: PAT covers all important items or dimensions
Nb: Each tool receives 2 points if it contains both
psychomotor/visual assessment of pain (eg,
posture, comfort, activity, and demeanour) and
interactive assessment of pain (eg, response to
palpation of potential pain loci), 1 point, if it
contained only psychomotor/visual assessment or
only interactive assessment of pain, and 0 points, if
it did not cover either of these dimensions/
indicators of content validity.
1: PAT covers important items or dimensions to
a moderate extent
1 1 Excellent
0: PAT does not seem to cover important items or
dimensions
1.2 Was the process of item selection described? 2: PAT was developed for a specific population,
using a theoretical or conceptual framework, or
a qualitative approach was used (eg, consultation
with clinicians)
1: PAT was developed based on literature review
only
1 1 Excellent
0: No information is provided about item selection
1.3 Was content evaluated by experts (content
validation)?
2: Content was evaluated by experts in the field, and
CVI was calculated for each item included in the
PAT
1: Content was evaluated by experts, but no CVI is
reported
0.83 0.81 Excellent
0: No information is provided about content
validation
1.4 Are limitations of some items presented or
discussed?
1: No limitations or if any limitations, they are
presented and item modifications have been made
or precautions have been stated
1 1 Excellent
0: No information is provided
2.1 Was internal consistency (Cronbach’s a coefficient)
of the PAT calculated?
2: 0.70 , a , 0.90
1: 0.60 , a # 0.70 or a $ 0.90 1 1 Excellent
0: a # 0.60 or no information provided
2.2 Was interrater reliability (Cohen’s kappa coefficient
if quantitative) calculated?
2: kappa.0.60 or intraclass correlation coefficient
(ICC) . 0.80
1: 0.60 $ kappa .0.40 or 0.60 , ICC #0.80 1 1 Excellent
0: kappa #0.40, ICC #0.60 or no information
provided
2.3 Was interrater reliability tested with other raters
besides the research team?
1: Other raters than the research staff members
were involved
0: Only research staff 0.83 0.81 Excellent
Members were involved
2.4 Was intrarater reliability tested? 2: kappa .0.60 or ICC .0.80
Optional—to be examined if ICC ,0.80 for
interrater reliability.
1: 0.60 $ kappa .0.40 or 0.60 , ICC # 0.80 1 1 Excellent
0: kappa #0.40, ICC #0.60 or no information
provided
3.1 What is the total of participants for the purpose of
testing the PAT?
2: N . 50
1: 20 , N # 50 0.83 0.81 Excellent
0: N # 20
(continued on next page)
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to the panel for individual rating of relevance as well as evaluation of
the clarity of item construction andwording. Participantswere asked
toaccept, reject, or suggestmodification topoints arising from round
1 relating to existing items or suggest additional items within each
domain.
Information acquired from round 2was then incorporated into the
round 3 questionnaires with the addition of the participant’s own
ratings and comments for each item as a reminder. Thus, separate
round 3 questionnaires were developed for each member of the
expert panel. Panel members reviewed and rerated the items in the
light of new information from the opinion of the group as a whole.
Consensus for inclusion of each itemwas predefined as acceptance
by 4 or more members of the expert panel (.4/6, .66%) without
any further modification being recommended by any of the
endorsing members. Any modifications were to be rated individually
in a subsequent round, with consensus for inclusion being
predefined as previously described.
2.4. Content validation
The panel of experts reviewed the content and relevance of the
CATRAS and evaluated the appropriateness of each item of the
tool as well as the tool’s relevance as a whole using the following
Likert-type scheme: 1 5 not relevant, 2 5 somewhat relevant,
3 5 quite relevant, and 4 5 very relevant.28
2.4.1. Item-level content validity index and kappa analysis
For each item of the CATRAS, the content validity (item-level
content validity index [I-CVI]) was calculated by dividing the
number of experts assigning a rating of either 3 or 4 by the total
number of experts—that is, the proportion of experts in
agreement concerning the relevance. For example, an item rated
as “quite relevant” or “very relevant” by 4 of 6 experts would have
an I-CVI of 0.67.37 The kappa coefficient for individual items was
also calculated using previously described methodology.50
Evaluation criteria for kappa used guidelines described in
Cicchetti and Sparrow (1981) and Fleiss et al. (2013): Fair 5
kappa of 0.40 to 0.59; Good 5 kappa of 0.60 to 0.74; and
Excellent 5 kappa .0.74.8,15 Items were considered to have
adequate content validity for inclusion in the CATRAS if they
achieved an I-CVI of 0.83 or greater and a kappa coefficient of
0.81 or greater. Kappa coefficients and I-CVI were calculated,
and based on published recommendations, a cutoff point for an
item to remain in the tool was predefined as 0.81 and 0.83,
respectively (reflecting one disagreement).30,37
Table 1 (continued)
CATRAS quality items and associated item-level content validity index (I-CVI) values and kappa coefficients (k).
Domain 3: grading of the pain assessment tool (PAT)
Question Scoring legend I-CVI k Evaluation
3.2 Criterion validation: Was the PAT correlated with the
current “gold standard” or with a measure
renowned in the field of interest if no “gold
standard” has been established?
2: r . 0.60 with the comparison measure
1: 0.40 , r # 0.60 1 1 Excellent
0: r # 0.40 or no information provided
3.3 Criterion validation: Was the sensitivity of the PAT
calculated?
2: Sensitivity $ 80%
1: 60% # sensitivity , 80% 1 1 Excellent
0: Sensitivity ,60% or no information provided
3.4 Criterion validation: Was the specificity of the PAT
calculated?
2: Specificity $ 80%
1: 60% # specificity , 80% 1 1 Excellent
0: Specificity ,60% or no information provided
3.5 Sensitivity to change: Was the PAT able to
differentiate between different situations (eg,
between pain and no pain; before and after the
administration of an analgesic; changes in health
status of the patient)?
2: A significant difference was found
1: A difference was found but was not significant 1 1 Excellent
0: No difference was found or no information is
provided
4.1 Is the PAT easily applied to the clinical setting? 1: PAT is short and manageable
0: PAT is more complex or no information is
provided
1 1 Excellent
4.2 Are directives of use of the PAT clearly described? 1: Yes, directives of use including the scoring
method are described
0: No information about directives of use is provided 1 1 Excellent
5.1 Was the relevance of the PAT or impact of its
implementation in patient outcomes examined?
1: PAT is considered to be useful and relevant to
practice by more than 80% of clinicians; use of the
PAT yielded a significant change into practice (eg,
better use of medication and increase in patients’
assessments)
1 1 Excellent
0: PAT is not considered to be useful/relevant to
practice by more than 20% of clinicians; use of the
PAT did not yield a significant change in practice or
no information provided
Evaluation criteria for kappa used guidelines described in Cicchetti and Sparrow (1981) and Fleiss et al. (2013): Fair 5 kappa of 0.40 to 0.59; Good 5 kappa of 0.60 to 0.74; and Excellent 5 kappa . 0.74.8,15
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2.4.2. Scale-level content validity index
The content validity of the tool as a whole (scale-level CVI [S-CVI])
was evaluated using previously describedmethodology, whereby
the S-CVI is calculated as the average I-CVI across all items of the
tool.37 Based on published recommendations, the minimum S-
CVI required for the CATRAS to achieve content validity for the
tool as a whole was predefined as 0.90.37,49
2.5. Development of the quantitative aspects of the
assessment tool (CATRAS)
A final list of quality items that achieved consensus agreement
from the panel of experts was collated by the working group.
Items were grouped within their respective domains and
weighted to reflect their importance within each domain.
(1) Domain 1—LOE: The highest score of 6 was attributed to the
strongest LOE (LOE 1) and the lowest score of 1 to the
weakest LOE (LOE 6) (Supplemental Table, available at http://
links.lww.com/PR9/A29).
(2) Domain 2—Methodological soundness: The LOE of a study
(step 1) must be established before assessment of its
methodological soundness (Supplemental Table, available at
http://links.lww.com/PR9/A29). Domain 2 consists of a list of
methodological quality items (step 2 categories A–E) relating
to the LOE assigned in step 1 (Supplemental Table, available
at http://links.lww.com/PR9/A29). The overall methodological
soundness is defined by 3 quality terms, as either: “good,”
“fair,” or “poor.” Studies are to be assigned the quality-term
“good” if they contain most or all the relevant quality items,
“fair” if they contain some of the relevant quality items, and
“poor” if they contain only a few of the relevant quality items
but were considered to be of sufficient value to warrant
inclusion in the next step of the review. The 3 quality terms
“good,” “fair,” and “poor” were given a score of 3, 2, and 1,
respectively.
(3) Domain 3—Grading of the PAT: Itemswere assignedweighted
scores representing those ascribed by Gélinas.16
The sum total of all weighted items within each individual
domain was transcribed into a percentage by dividing the
attributed score by the maximum possible score of each
respective domain. Transcription of the score into a percentage
allowed for standardisation between the 3 domains of the
CATRAS. Each domain was assigned equal weighting. Members
of the expert panel were then asked to accept, reject, or suggest
modification to the allocation of item scores and weightings.
Consensus for inclusion of item scores and weightings were
predefined as acceptance by 4 or more members of the expert
panel without any further modification being recommended by
any of the endorsing members. Any modifications were to be
rated individually in a subsequent round, with consensus for
inclusion being predefined as previously described.
3. Results
3.1. Evaluation for completeness and development
of consensus
During the round 1 review of the draft CATRAS, no additional
domains were deemed necessary by any member of the expert
panel. The following item was added to the methodological
soundness domain in each of the 5 possible categories (A–E):
“Was ethical/institutional review board approval of the study
stated?” This addition was unanimously accepted during rounds
2 and 3 of the review process, and no further items were modified
or excluded.
3.2. Content validation
3.2.1. Item-level content validity index and kappa analysis
The 67 items of the 3 domains were reviewed (Table 1). Fifty-
seven (57/67; 85%) items received 100% agreement by all 6
members of the expert panel (I-CVI 5 1; kappa coefficient 5 1).
Ten (10/67; 13%) items received 83% agreement (I-CVI 5 0.83;
kappa coefficient 5 0.81).
3.2.2. Scale-level content validity index
The content validity of the final remaining 67 items of the CATRAS
resulted in a 97% (S-CVI 5 0.97) agreement, indicating that the
tool achieved excellent content validity.
3.3. Development of the quantitative aspects of the
assessment tool (CATRAS)
After content validation, the working group assigned scores and
weightings to the 67 quality items and the associated domains.
The assigned scores and weightings for all 67 quality items and
the associated domains were unanimously accepted without
modification by the expert panel. The final results derived from
application of the CATRAS are 3% scores (ie, one for each
domain). The final version of the CATRAS is shown in the
Supplemental Table (available at http://links.lww.com/PR9/A29).
An example of the application of the CATRAS can be found in
(Supplemental Appendix 1, http://links.lww.com/PR9/A22).
4. Discussion
In 2014, a working group (L.N.W. and S.H.B.) found no evidence
of a published CAT designed specifically to evaluate the quality of
published analgesia studies in any species. To address this
absence, the authors designed and validated a 67-item CAT
(Supplemental Table, available at http://links.lww.com/PR9/A29)
that incorporates 3 domains (LOE, methodological soundness,
and grading of the PAT).
Level of evidence is used by many review processes to create
order and simplicity from the heterogeneity of published studies,
and is assigned according to the study type and its inherent
likelihood to exclude bias.4,31 The methodological quality and
transparent reporting of an analgesia study is a key factor to
consider when assessing its translational value.36,41 The quality
items listed within the CATRAS to assess methodological
soundness are primarily based on those used in the RECOVER
initiative process, which were originally derived from CATs
designed by the OCEBM.4,6 In addition, all the quality items
described in methodological soundness category A of the
CATRAS are part of the Consolidated Standards of Reporting
Trials (CONSORT) 2010 “checklist of information to include when
reporting a randomised trial.”35 The CONSORT statement was
developed to improve the standard of reporting of randomised
controlled trials for medical interventions.3 Furthermore, the
methodological soundness domain of the CATRAS also complies
with the Animal Research Reporting In Vivo Experiments
(ARRIVE) guidelines methodology section, which highlights
details of bias reduction tactics such as sample size calculation,
random allocation to groups, and observer blinding.25,41 After
recommendations from the panel of experts, the item “was
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ethical/institutional review board approval of the study stated?”
was added to the methodological soundness domain (categories
A, B, C, D, and E) both to strengthen the tool and to promote
ethical research.
Content validity concerns the degree to which a scale has an
appropriate sample of items to represent the construct of interest;
that is, whether the domain(s) of content for the construct is
adequately represented by the items.37 Content validity of the
CATRAS was reviewed using a panel of 6 experts selected
according to previously defined criteria.12,18 In addition, wide-
spread geographical distribution of the panel members (Australia,
Brazil, Canada, United Kingdom, and United States) allowed for
differences in colloquial terms that could affect instrument
comprehension by many diverse groups.18
There are potential biases in the methodology used. First, the
statements are not an inventory of every aspect of methodology
that could impact on trial quality. In an attempt to reduce the
likelihood of this bias, the working group obtained consensus
opinion from individuals with direct experience of conducting
studies involving assessment of pain; as knowledge of the subject
matter is considered the most significant assurance of a valid
outcome using the Delphi methodology.47 Second, the reliability
of the findings relating to validity coefficients may have been
influenced by including the same individuals in both the content
consensus and subsequently also as raters during the content
validity process. The working group attempted to minimise this
bias by both sequencing the order of the tasks and by their
temporal separation: the consensus process occurred approx-
imately 10 months before the content validity process.
A widely accepted method of quantifying content validity for
multi-item tools such as CATRAS is the CVI based on expert
rating of relevance.37 The CVI is an index of consensus and the
extent to which experts share a common interpretation of the
construct of a tool.46 A CVI was calculated for each quality item of
the 3 domains (I-CVI) as well as for the overall CATRAS as the
whole tool (S-CVI), thereby providing an index of interrater
agreement. Critics of the CVI cite concerns about the possibility of
inflated values because of the risk of chance agreement.50 In an
attempt to address this issue, the current study used a previously
described modified kappa-like index that adjusts each I-CVI for
chance agreement or disagreement.37 Fifty-seven items received
100% agreement (I-CVI 5 1); and ten items received 83%
agreement (I-CVI 5 0.83); there was no consistency observed in
relation to individual members of the expert panel who rejected
items of the CATRAS (including geographical location of the
experts). Based on previously published guidelines citing the
acceptable I-CVI in relation to the number of expert raters, these
items of the CATRAS achieved adequate item-level content
validity. In addition, using previously described evaluation criteria
for kappa, these items were considered to have excellent
agreement on relevance.8,15
Assessment of the S-CVI for the combined final 67 items of the
CATRAS resulted in a 97% (0.97) agreement, indicating that the
tool achieved excellent content validity. This result is considerably
higher than published recommendations of the minimum S-CVI
required for validation. Critical appraisal tool developers often set
a criterion of 80% (0.80) or better agreement among expert
reviewers as the lower limit of acceptability for an S-CVI.11
However, we chose to adopt the more stringent recommenda-
tions of Waltz et al.49 who set the lower limit of acceptable
agreement at 90% (0.90).
It is widely accepted that interpretation of the results of
a particular study should be informed by the quality of all
aspects of the trial: the higher the quality, the greater the
confidence in the validity and utility of the findings.51 When
evaluating analgesia studies, the quality of the PAT used must
be considered as a significant factor determining the quality of
the report. Previously, consideration of the impact of the PAT
on the strength of evidence has not been possible. De-
velopment of the CATRAS may now enable evaluation of the
strength of findings from published analgesia studies based on
a more thorough assessment of quality. The need to assess
the original or revised literature for the purpose of grading the
PAT may decrease the time efficiency of the CATRAS and
might be considered a limitation by some users. Future work
could streamline this process by establishing precalculated
grades for the commonly used PATs. Another potential
limitation of the CATRAS could be that because of the
nonlinearity of both visual analogue scales and numeric rating
scales, calculation of sensitivity and specificity (domain 3, item
3.3 and 3.4) may not be relevant for assessing these scales
and as such they may be slightly downgraded by up to 4% of
the overall possible score for domain 3. An interpretation of the
results obtained from the grading of a PAT can be found in
(Supplemental Appendix 2, http://links.lww.com/PR9/A23).
In evaluating the quality of published analgesia studies, it is
important to consider both the analgesic efficacy and the safety of
the drugs and regimens used.9 The CATRAS does not assess
patient safety outcomes, and this may be considered a limitation.
In recent years, there has been growing interest in assessment
of pain in animal subjects as well as in human patients incapable
of self-reporting, with the number of newly developed PATs
growing rapidly.5,10,13,26,27,38,45 It is the responsibility of
researchers, funding agencies, and journals to prevent excessive
growth of nonvalidated PATs in circumstanceswhere appropriate
and validated tools already exist. Further psychometric evaluation
of existing PATs should be given priority over developing new
tools for future use. Valid, practical, and reliable PATs can add to
the body of knowledge about pain and help improve its treatment.
The final results derived from application of the CATRAS are
3% scores (ie, one for each domain). Illustration of these results
should be at the discretion of the investigators; however, a radar
chart would allow for a two-dimensional representation of the 3%
scores on axes starting from the same point (Supplemental
Appendix 1, http://links.lww.com/PR9/A22). Charting of the data
in this way enables clear visual representation of the quality of
a specific analgesia study in relation to the LOE, methodological
soundness, and grading of the PAT.
Central to the practice of evidence-based medicine (EBM) is
the process of asking well-focused questions, searching for
the best available evidence, critically appraising that evidence
for quality and validity, then applying the results to improve
patient outcomes.20,42 The CATRAS is designed to facilitate
the practice of EBM by enabling a quantitative quality
assessment of an individual published study’s evidence
supporting (or rejecting) the clinical question being investi-
gated. The CATRAS can be used to explore the influence of
study quality or design methodology on the strength of the
results and conclusions. We endorse the use of a systematic
EBM approach that provides an explicit framework for
formulating the clinical question or statement under investi-
gation in terms of its 4 key parts—Problem/Population,
Intervention, Comparison, and Outcome (PICO).1
The CAT developed in this study offers several benefits for
assessing the quality of analgesia studies involving subjects
incapable of self-reporting pain: its content was developed
through the consensus of experts; it captures features of study
design methodology, which are widespread in this field; and
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content validation has been established. The next step in the
development of this important tool would be to apply theCATRAS
in a systematic review of the literature focused on questions
arising from analgesia studies.
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